CD33 and acute myeloid leukemia: While elegant strategies have been developed to reduce the risk of ‘on target/off target’ toxicity of AML-redirected CAR T cells including deleting CD33 in HPCs14, there is a continued need to discover antigens that are expressed solely on AML blasts and not on HPCs or mature cells of the myeloid lineage.